<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To estimate <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risks for patients with myotonic <z:mpath ids='MPATH_554'>dystrophy</z:mpath>, given that increased risks for <z:hpo ids='HP_0002664'>neoplasms</z:hpo> in association with myotonic <z:mpath ids='MPATH_554'>dystrophy</z:mpath> type 1 and type 2 have been suggested in several studies but the risks of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> have not been quantified </plain></SENT>
<SENT sid="1" pm="."><plain>PATIENTS AND METHODS: A cohort of 307 patients with myotonic <z:mpath ids='MPATH_554'>dystrophy</z:mpath> identified from medical records of Mayo Clinic in Rochester, MN, from January 1, l993, through May 28, 2010, was retrospectively analyzed </plain></SENT>
<SENT sid="2" pm="."><plain>We estimated standardized incidence ratios (SIRs) of specific <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> for patients with myotonic <z:mpath ids='MPATH_554'>dystrophy</z:mpath> compared with age- and sex-specific <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> incidences of the general population </plain></SENT>
<SENT sid="3" pm="."><plain>Age-dependent cumulative risks were calculated using the Kaplan-Meier method </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: A total of 53 cancers were observed at a median age at diagnosis of 55 years </plain></SENT>
<SENT sid="5" pm="."><plain>Patients with myotonic <z:mpath ids='MPATH_554'>dystrophy</z:mpath> had an increased risk of <z:e sem="disease" ids="C0007115" disease_type="Neoplastic Process" abbrv="">thyroid cancer</z:e> (SIR, 5.54; 95% confidence interval [CI], 1.80-12.93; P=.001) and <z:hpo ids='HP_0012054'>choroidal melanoma</z:hpo> (SIR, 27.54; 95% CI, 3.34-99.49; P&lt;.001) </plain></SENT>
<SENT sid="6" pm="."><plain>They may also have an increased risk of <z:e sem="disease" ids="C0153594" disease_type="Neoplastic Process" abbrv="">testicular cancer</z:e> (SIR, 5.09; 95% CI, 0.62-18.38; P=.06) and <z:hpo ids='HP_0012125'>prostate cancer</z:hpo> (SIR, 2.21; 95% CI, 0.95-4.35; P=.05) </plain></SENT>
<SENT sid="7" pm="."><plain>The estimated cumulative risks at age 50 years were 1.72% (95% CI, 0.64%-4.55%) for <z:e sem="disease" ids="C0007115" disease_type="Neoplastic Process" abbrv="">thyroid cancer</z:e> and 1.00% (95% CI, 0.25%-3.92%) for <z:hpo ids='HP_0012054'>choroidal melanoma</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>There was no statistical evidence of an increased risk of brain, breast, colorectal, lung, renal, bladder, endometrial, or <z:e sem="disease" ids="C1140680" disease_type="Neoplastic Process" abbrv="">ovarian cancer</z:e>; <z:hpo ids='HP_0002665'>lymphoma</z:hpo>; <z:hpo ids='HP_0001909'>leukemia</z:hpo>; or <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: Patients with myotonic <z:mpath ids='MPATH_554'>dystrophy</z:mpath> may have an increased risk of <z:e sem="disease" ids="C0007115" disease_type="Neoplastic Process" abbrv="">thyroid cancer</z:e> and <z:hpo ids='HP_0012054'>choroidal melanoma</z:hpo> and, possibly, testicular and <z:hpo ids='HP_0012125'>prostate cancers</z:hpo> </plain></SENT>
</text></document>